Orasis is an ophthalmic pharmaceutical company launching a best-in-class, FDA-approved prescription eye drop called Qlosi for treating presbyopia, the gradual vision loss of near objects.

Orasis has developed a proprietary eye drop formulation that delivers a low concentration of the active ingredient pilocarpine in a preservative-free near-neutral pH drop, with equal efficacy but greater comfort than is possible with competing products. The lower dose results in fewer and less severe side effects (a historic barrier to commercial adoption) and positions Qlosi with a strong product-market fit for early-stage presbyopia patients seeking alternatives to lens-based treatment. Orasis addresses a $10B market opportunity in early-stage presbyopia that is primed for the arrival of a novel drug-based treatment option.